1. Home
  2. MTEK vs IMRN Comparison

MTEK vs IMRN Comparison

Compare MTEK & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.67

Market Cap

12.6M

Sector

N/A

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.98

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
IMRN
Founded
2008
1994
Country
Israel
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
12.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
MTEK
IMRN
Price
$1.67
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
88.0K
84.6K
Earning Date
09-26-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,375,716.00
$4,777,422.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.63
52 Week Low
$1.03
$0.68
52 Week High
$4.27
$2.39

Technical Indicators

Market Signals
Indicator
MTEK
IMRN
Relative Strength Index (RSI) 64.42 46.14
Support Level $1.51 $0.93
Resistance Level $1.89 $1.05
Average True Range (ATR) 0.14 0.10
MACD 0.03 0.02
Stochastic Oscillator 65.74 38.55

Price Performance

Historical Comparison
MTEK
IMRN

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: